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Abstract 
Background. Details of current UK drugs and allergen exposure were needed for interpretation 
of reports of perioperative anaphylaxis to the Sixth National Audit Project (NAP6).  
Methods. We surveyed United Kingdom National Health Service hospitals for this purpose. We 
also surveyed anaesthetic activity, which is reported separately. Results are compared to a 
similar 2013 survey for NAP5 where relevant. 
Results. From 342 (96%) hospitals we collected 15 942 forms: equating to an annual caseload 
for anaesthetists of 3 126 067 including 2 394 874 general anaesthetics (GAs). Propofol was the 
dominant induction agent (90.4%) and used more often in Caesarean section than in NAP5. 
Nitrous oxide use has fallen 30% since NAP5. Neuromuscular blocking agents were used in 
47.2% of GAs. Suxamethonium use has fallen. Use of reversal agents is overall unchanged, but 
sugammadex use increased 4-fold. Analgesics were used in 88% of cases: opioids 82.1%; 
paracetamol 56.1% and non-steroidal anti-inflammatory drugs 28.3%.  Overall antibiotic use 
was 57.2% of cases and >3 million annual perioperative administrations: gentamicin 19.7%, co-
amoxiclav 17.0% and cefuroxime 13.6% were prominent. In 25% of teicoplanin or vancomycin 
uses allergy history influenced drug choice. Local anaesthetics were used in 74.2% cases and 
68.9% of GAs. Anti-emetics were used in 73.1% of cases: during GA, ondansetron in 78.3% and 
dexamethasone in 60.4%. Blood products were used in ≈3% of cases, synthetic colloids in <2% 
(starch in only 1 in 600 cases), tranexamic acid in ≈6%. Chlorhexidine and iodine exposure were 
reported as 73.5% and 40.0% of cases and a latex-free environment in 21.2%. Exposure to bone 
cement, blue dyes and x-ray contrast were each reported in 2-3% of cases. 
Conclusions. This extensive national survey of anaesthetic practice provides new insights into 
drug uses and allergen exposures in perioperative care. It is important for use as denominator 
in the main NAP6 analysis and the data provide significant insights into many aspects of 
perioperative practice. 
 
Keywords 
audit; anaesthesia; allergen exposure; drugs 
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The Royal College of Anaesthetists National Audit Projects (NAPs) study major complications of 
anaesthesia and concurrently review current practice and use the findings to improve patient care. 
The Sixth National Audit Project of the Royal College of Anaesthetists (NAP6), is a large-scale 
prospective service evaluation of perioperative anaphylaxis across the hospitals of the United 
Kingdom. It has gathered comprehensive quantitative and qualitative information on these events, 
enabling the anaesthetic and allergy/immunology communities to collaborate in order to make 
recommendations for the improvement of the quality of patient care.
1-3 
 
  
During the NAP6 project a one-year registry was established to collect reports on all suspected cases 
of perioperative anaphylaxis in 2015-16. This provided a numerator, but in order to interpret the 
results of the registry and to estimate the incidence of perioperative anaphylaxis overall and of its 
causes (drugs/other substances), contemporary information about anaesthetic activity, drug use and 
exposure to other relevant substances (such as antiseptics and dyes), was required. This data would 
provide a denominator.   
 
In 2013, the NAP5 project reported a similar activity and drug survey,
4
 providing information on 
aspects of anaesthetic activity and some drug uses, but insufficient for the needs of NAP6. Published 
Hospital Episode Statistics (HES)
5
 show an increase in inpatient and day case procedures since 2013, 
but do not give detailed information on anaesthetists’ involvement. NHS Maternity Statistics show a 
slight decrease in deliveries in NHS hospitals since 2013, of which 60% involved anaesthetic 
intervention.
6
 Such changes over time mean that figures collected for NAP5 may not necessarily be 
applicable for NAP6. In addition, the NAP5 survey did not collect sufficient detailed information on 
perioperative administration of drugs and other potential allergens. National data for hospital drug 
usage is collected by IQVIA
TM
 and recorded in the Hospital Pharmacy Audit Index (HPAI) database.
7
 
This records all medication that is issued by pharmacies for use on wards, in operating theatres and 
on patient discharge. It does not, however, record what is administered to the patient nor in what 
context a certain drug is delivered, so does not provide information on actual perioperative drug use. 
 
An ‘Activity/Allergen survey’ was therefore designed to collect such data and this is reported here. 
During the survey, anaesthetic activity data and drug/allergen exposure data was collected. The 
‘Activity survey’ is reported separately
8
 and here we report results of the ‘Allergen survey’  
Methods 
The NAP6 project was defined as a service evaluation by the Health Regulatory Authority 
therefore did not require National Research Ethics Service approval. All NHS hospitals, Trusts 
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and Boards in the UK believed to undertake surgery were invited to, and did, volunteer a local 
co-ordinator (LC) who supervised all aspects of the study at that location. 
 
Local co-ordinators (LCs) were approached at 356 NHS hospitals and organised data collection 
from every perioperative case involving care delivered by an anaesthetist for a period of 48-
hours. This included all adult and paediatric cases requiring general, regional and local 
anaesthesia, as well as sedation if involving an anaesthetist. Obstetric cases included epidural 
pain relief in labour. Any cases where sedation or local anaesthesia was delivered by a non-
anaesthetist were not included. Routine sedation in intensive care was excluded. 
 
The majority of data collection took place between 13th and 31st October 2016, during which 
time there were no public holidays; seven sites collected data between January and June 2017 
for logistical reasons.  Data were recorded using a paper proforma (Appendix 1) and each form 
was transferred, using optical character recognition, to electronic storage. Each hospital was 
randomised to record activity on two consecutive days of the week, with specialist hospitals 
(cardiac, neurology or paediatric centres) block-randomised separately to prevent skewed 
allocation. Patient characteristics, method of anaesthesia, anaesthetic staffing, induction 
location, type of monitoring and drugs/substances used, and the presence of any allergy history 
were reported for each case. Local co-ordinators were also asked to record a capture rate at 
their site to estimate the proportion of cases for which a completed case report form was 
submitted. Data regarding staffing, workload and anaesthetic activity are reported separately.
8
 
 
Data were analysed using IBM SPSS Statistics for Windows, Version 23 (IBM Corp. Armonk, New 
York). An annual caseload was estimated by multiplying the number of cases by a scaling factor. 
This factor was calculated by converting the number of cases from two days to one week 
(scaling factor of 3.5), and from one week to one year (scaling factor of 50.6, the effective 
number of working weeks in 2016 (Appendix 2). This was then divided by the hospital response 
rate, the mean reported capture rate at individual sites and the proportion of interpretable 
forms, to account for cases that were not reported. Responses marked as ‘unknown’ and 
incomplete fields were combined and reported as ‘unknown’.  
  
Here we report data relevant to allergen exposure in the perioperative period and relating to 
anaesthetist practices in using certain drugs. Where relevant this data is compared to that from the 
2013 NAP5 study.
4
 
Results  
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Out of 356 sites approached, 342 took part in the survey submitting a total of 15 942 forms. Applying 
the calculated scaling factor, the estimated annual caseload was 3 126 067. The distribution of 
numbers of forms returned from each hospital are shown in Supplementary figure 1. Where relevant, 
illogical forms (e.g. patients reported to be awake when neuromuscular blocking agents (NMBAs) 
were used), were excluded but these represented <1.0% of any analysis. 
 
The scaling factor was 196.09. Patient Characteristics are described in the accompanying paper.
8
  
Intended conscious level was reported as general anaesthesia (GA) 76.6% (annual estimate 2 394 
847) sedation 8.2% (258 250 cases) and awake 14.2% (442 379 cases) (Supplementary table 1).  
Anaesthetic Drug Use 
Previous Allergy History and Choice of Drugs 
Choice of drugs was reported as influenced by previous allergy history in 1 351 cases (8.6% of 15 723 
responses); in 64% because of allergy to an antibiotic, 35% allergy to another drug and in 3% to both.  
Number of Drugs Used per Procedure 
The median number of drugs given in each procedure was 8, minimum 1 and maximum 20 
(Supplementary figure 2). 
Induction Agents 
In terms of allergen exposure: induction agents were used in 13 019 cases including all intended 
conscious levels: estimated annual caseload was 2 552 896 (Supplementary table 2). 
 
For cases performed with general anaesthesia 15% of returns indicated two induction agents with a 
volatile reported as an induction agent in 14.8% of cases and a combined volatile/IV induction in 9%: 
of those with volatile co-induction 51% were adults (Supplementary table 2). As some respondents 
had likely included both an intravenous and a volatile agent as an ‘induction agent’ to determine the 
primary induction agent we only analysed a subset of these cases where one agent was used. 
 
Considering only patients who received general anaesthesia induced with a single agent, or a single 
agent and midazolam, (n=10 969) the distribution of drugs used was propofol 90.4%, and thiopental 
1.6%, ketamine 0.7%, etomidate (0.3%), sevoflurane (6.2%) other volatile agents (0.1%). Midazolam 
was used as a sole agent in 0.1% of cases (predominantly urgent/emergency cases in ASA 4 - 5 
patients) and as a co-induction agent in 7.5%. These proportions did not vary significantly whether 
midazolam was included or not (Supplementary table 3). These results suggest a small reduction in 
use of thiopental (1.6% from 2.9%) and an equivalent increase in the use of propofol (90.4% from 
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88%) since 2013.
4
Cases involving a volatile agent alone for induction were predominantly children 
(86%).  
 
Propofol was the most widely used induction agent in all groups: 57.7% in children (<16 yrs), 96.2% in 
adults and 89.7% in patients aged >65 yrs. Distribution of induction agents used by age is shown in 
Supplementary figure 3). Sixty four patients undergoing Caesarean section, received general 
anaesthesia; thiopental was used in 62.7% (97% in NAP5), propofol in 29.7%, midazolam and 
ketamine in 1.6% each. Etomidate and sevoflurane were not used (Supplementary figure 3). 
Maintenance Agents 
Amongst general anaesthetics where a maintenance agent was used, as inhalational agents was used 
in 94.6%; sevoflurane in 69.9% (58.5% in NAP5), nitrous oxide in 17.1% and propofol in 8.7%. In 2.2% 
of cases, both a volatile agent and propofol were used as maintenance agents (Supplementary table 
4).  
 
The drug exposure survey showed that 293 (14%) of paediatric cases were administered with 
sevoflurane only (both for induction and maintenance) with no other agents. Thus a large cohort of 
children had an extremely low risk technique as far as antigen exposure is concerned. 
 
The use of maintenance agents by age and in Caesarean sections is illustrated in Supplementary 
figure 4; sevoflurane was the preferred maintenance agent across all age groups and indications.  
Induction and maintenance exclusively with sevoflurane was reported in 2.8% of general 
anaesthetics: 14.5% of paediatric and 0.4% of adult general anaesthetics. Sevoflurane was used 
during general anaesthesia for 90.6% Caesarean sections. Nitrous oxide was reported to be used in 
17.1% of cases, 30.1% in children and 60.9% during Caesarean section: a fall from 2013: 25% overall, 
45% in children and 71.4% in Caesarean section. Nitrous oxide was used most frequently during 
general anaesthesia in orthopaedics/trauma, general surgery and ENT, perhaps associated with the 
increased numbers of paediatric in these specialties.
4 
Neuromuscular Blocking Agents (NMBAs) 
NMBAs were reported to be used in 5760 (47.2%) cases receiving GA; estimated annual caseload       
1 129 478. Use of NMBAs and estimated annual caseload are detailed in Supplementary table 5. 
Of those receiving NMBAs, 88.8% received non-depolarising NMBAs only, 4% suxamethonium only 
and 7.2% both suxamethonium and a non-depolarising NMBA (Supplementary figure 5). Use of 
different NMBAs in all GA cases is illustrated in Figure 1. Atracurium (23.2%) and rocuronium (19.2%) 
were the agents most commonly used, followed by suxamethonium (5.3%), with cisatracurium, 
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mivacurium, vecuronium and pancuronium being used rarely. The distribution of NMBAs was not 
captured in the NAP5 survey. 
 
(Figure 1 near here)  
 
Within age groups, NMBAs were used in 23% of children, 49.6% of adults and 58.2% of elderly 
patients, and in almost all general anaesthetic Caesarean sections (98.4%); distribution shown in 
Figure 2 and Supplementary figure 6. These figures are stable since NAP5. 
 
(Fig 2 near here) 
 
In most specialties atracurium and rocuronium were used predominantly, with the main exceptions 
being cardiac surgery, obstetrics and psychiatry. In cardiac surgery, pancuronium and vecuronium 
were used, in 25.7% and 17.9% of cases, respectively. All psychiatry cases received suxamethonium 
and 1.3% also received atracurium. The distribution of NMBAs in obstetrics was suxamethonium 
72.5%, atracurium 35.2% and rocuronium 23.1%; 16.9% received only a non-depolarising NMBA.  
 
Distribution of NMBA use by specialty and by clinical setting is shown in Supplementary figures 6-8.  
One notable finding is that in ICU, suxamethonium use was absent and rocuronium was used more 
often (>50%) than in any other location. Conversely in the emergency department, suxamethonium 
was widely used and rocuronium notably less often (supplementary Figure 9). 
 
When suxamethonium was used, propofol was the induction agent in 73.6% of cases and thiopental 
in 22.4%, with other agents used rarely. Supplementary figure 10 shows use of induction agents by 
NMBA. Use of suxamethonium and rocuronium by age and NCEPOD priority is depicted in 
Supplementary figure 11. 
Reversal Drugs 
Reversal agents were used in 62.2% of patients undergoing a general anaesthetic with an NMBA. In 
cases involving a non-depolarising NMBA, reversal was used in 64.6% (68% in NAP5
1
). Neostigmine 
was used in 59.4% (91.9% of all reversed cases) and sugammadex in 5.9% (9.1% of reversed cases). 
Sugammadex is now used in almost four-fold more cases than seen in 2013 (2.2% of reversals).
4
 
Supplementary table 6 details reversal agents used and estimated annual caseloads. 
Analgesics 
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Analgesics were used in 88.2% of all cases (any intended conscious level); estimated annual caseload 
2 755 849. Opioids were used in 82.5% of all cases. Paracetamol was administered in 56.1% and a 
non-steroidal anti-inflammatory drug in 28.3% of cases.   
 
Fentanyl was the most frequently used opioid, administered in 61% of cases, followed by morphine 
in 26.5% and remifentanil in 8.7% of cases. Diclofenac was the most commonly used NSAID, followed 
by parecoxib and ibuprofen. Clonidine was administered in 0.9% of cases. Use of each analgesic drug 
is illustrated in Figure 3 and estimated annual caseload in Supplementary table 6.  
 
(Fig 3 near here) 
 
Opioids were used more frequently during general anaesthesia than in other cases. At least one 
opioid was used in 99.8% of general anaesthetics: fentanyl in 73.7%; morphine in 33.0%, remifentanil 
in 10.7%. Paracetamol was used in 67.5%. The distribution of use of different analgesic drugs by 
intended conscious level is illustrated in Supplementary figure 12.  
Antibiotics 
Antibiotics were used in 57.2% of all cases, with an estimated annual caseload of 1 787 360. 
Gentamicin (19.7%), co-amoxiclav (17.0%) and cefuroxime (13.6%) were the three most commonly 
used antibiotics (Figure 4), with estimated annual caseloads of around a half a million for the former 
two and approximately 400,000 for the latter. Supplementary table 8 details antibiotics used and 
estimated annual caseloads. 
 
(Fig 4 near here) 
 
In a quarter of cases where teicoplanin or vancomycin were used (287/1120 and 23/90 cases, 
respectively), their choice was reported to be influenced by past allergy history to an antibiotic 
(Supplementary figure 13). 
 
The greatest proportion of all antibiotics use by surgical specialty was in orthopaedics/trauma, 
accounting for 23.1%, followed by general surgery (14.4%), obstetrics (9.2%), urology (8.9%) and 
gynaecology (6.5%; Figure 5). The proportion of cases administered antibiotics by specialty was, in 
descending order cardiac surgery 97.2%; neurosurgery 89.4%; urology 81.7%; thoracic surgery 80.9%; 
orthopaedics/trauma 69.9% and general surgery 60.3% (Figure 5).  
 
(Fig 5 near here) 
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Co-amoxiclav was commonly used across most specialties. In ophthalmology, cefuroxime was the 
most common antibiotic used. In cardiac surgery and cardiology, the dominant antibiotic was 
gentamicin, with flucloxacillin, cefuroxime and teicoplanin also being frequently used (Figure 6). Use 
of antibiotics in orthopaedics/trauma was almost evenly spread between gentamicin (32.7% of all 
orthopaedics/trauma procedures), teicoplanin (21.3%), flucloxacillin (18.2%) and cefuroxime (17.9%, 
Figure 6). 
 
(Fig 6 near here) 
 
Co-amoxiclav  
Co-amoxiclav was the most commonly used antibiotic: 21.6% of all antibiotic uses. It was regularly 
used in general surgery (27.5% of all cases receiving this drug), gynaecology (15.4%) and obstetrics 
(13.6%). Choice of co-amoxiclav was not influenced by past allergy history (94.2%). 
Teicoplanin 
Teicoplanin accounted for 8.9% of all antibiotic administrations. It was used mainly in 
orthopaedics/trauma (17.5% of all cases receiving this drug), general surgery (16.9%) and 
gynaecology (10.8%). In 25.6% of cases receiving this antibiotic its choice was determined by 
previous history of antibiotic allergy. 
Local Anaesthetics 
Local anaesthetics (LA) administered by any route, were used in 74.2% of all cases and in 68.9% of all 
general anaesthetics. The proportion of LA drug use was bupivacaine 33.3%; lidocaine 32.0%; 
levobupivacaine 25.6%; ropivacaine, prilocaine and other LAs each <3% each. Supplementary table 9 
details LA use and estimated annual caseloads.  Use of LAs by conscious level is detailed in Figure 7. 
 
(Fig 7 near here) 
Anti-emetics 
Anti-emetics were used in 73.1% of all cases: ondansetron in 65.6% of all cases; dexamethasone in 
48.5%; cyclizine in 5.7%; all other anti-emetics <2% (Supplementary table 10 for details of anti-emetic 
use and estimated annual caseloads). During general anaesthesia, antiemetic use was higher: 
ondansetron 78.3% of cases and dexamethasone 60.4%. Ondansetron and dexamethasone were 
used in combination in 53.1% of all GA cases.  
IV Colloids and Blood Products 
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Intravenous colloids and/or blood products were used in 4.2% of all cases. Gelatin-containing 
products (1.7% of all cases) and red blood cells (1.5%) were the most frequently used products). 
Starch or starch-containing products (0.2% of all cases), albumin (0.1%), platelets (0.4%), fresh frozen 
plasma (0.5%) and specific coagulation factors (0.2%), were used uncommonly. Supplementary table 
11 details use of IV colloids and blood products and estimated annual caseloads. The surgical 
specialties that used the greatest proportion of IV colloids or blood products were orthopaedics/ 
trauma, general surgery, cardiac surgery and obstetrics (1.0%, 0.8% and 0.5% each, of all cases, 
respectively). The specialties that used IV colloids or blood products most frequently were cardiac 
surgery, other major operations and vascular surgery (56.6%, 16.7% and 13.6% of cases within each 
specialty, respectively).  Supplementary figure 14 details use of these substances by main procedure. 
There was no evidence that starch use was concentrated in a particular site or specialty. 
Drugs Affecting Coagulation  
Drugs affecting coagulation were used in 8.3% of all cases. Tranexamic acid was the most common 
drug used (5.9% of all cases), followed by heparin (2.7%). Protamine, aprotinin, vitamin K and other 
coagulation drugs (not specified) were used in less than 1% of all cases. Supplementary table 12 
details use of drugs affecting coagulation and estimated annual caseloads. Use of these drugs was 
mostly concentrated in orthopaedics, cardiac and vascular surgery (52.2%, 25.4% and 10.9% of all 
cases where a coagulation drug was used, respectively). Tranexamic acid was administered in 71% of 
cardiac surgery and 19% of orthopaedic operations.  
Antiseptics 
Use of antiseptics and estimated annual caseload is detailed in Supplementary tables 13 and 14.  
Chlorhexidine 
Chlorhexidine exposure was reported in 73.5% of all cases, mostly via skin prep by the anaesthetist 
(51.6% of all cases, accounting for 70.2% of all chlorhexidine-exposed cases) and/or the surgeon 
(44.7% of all cases, 60.7% of chlorhexidine-exposed cases), with very few cases reported to be via 
urethral exposure (3.3% of all cases), coated/impregnated CVC, surgical irrigation, or other (0.6% of 
all cases each for the latter three routes). Exposure to this antiseptic was reported to be unknown in 
0.9% of all cases and 23.6% of cases were reported to have no exposure. Chlorhexidine exposure was 
reported in more than two thirds of cases for most surgical specialties (Supplementary figure 15). 
Povidone-iodine 
Povidone-iodine exposure was reported in 40.0% of all cases, mostly via skin prep by the surgeon 
(36.7% of all cases, accounting for 91.7% of all povidone-iodine-exposed cases) or by the anaesthetist 
(6.6% of all cases, 16.4% of povidone-iodine-exposed cases), with minor contributions by surgical 
irrigation (0.9% of all cases) or other routes (1.0% of all cases). A total of 54.6% of cases were 
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reported to have no exposure. Povidone-iodine was used in less than half of cases for all surgical 
specialties except for ophthalmology, where its use was almost ubiquitous (95.6%), and 
neurosurgery, vascular, general surgery and plastics, where it was used in more than half of the cases 
(Supplementary figure 15). 
Latex 
More than two thirds of cases (69.7%) were reported to be exposed to latex, with the main route 
being latex gloves (64.3% of all cases, accounting for 92.1% of all latex-exposed cases). A latex-free 
environment was reported for 21.2% of all cases and latex exposure was unknown for 7.1%. 
Supplementary table 15 details latex exposure and estimated annual caseload. The specialty with 
highest rate of latex exposure was cardiac surgery (94.8% of cases) and the lowest was psychiatry 
(30.8%) (Supplementary figure 16). 
Miscellaneous Drugs / Substances 
Bone cement was used in 2.6% of all cases and in 11.8% of orthopaedics/trauma cases, with an 
annual caseload of 78,240. 
 
Blue dyes were used in 2.8% of all cases: patent blue in 2% and methylene blue in 0.9%. Both patent 
blue and methylene blue dyes were mostly used in general surgery: 29.8% and 35.3% of all cases 
receiving these dyes, respectively. 
 
X-ray contrast was used in 1.7% of all cases, mostly in urology, radiology and orthopaedics: 24.5%, 
22.3%, and 14.2% of all cases receiving X-ray contrast. 
 
Supplementary table 16 details use of the above substances and estimated annual caseload. 
 
Discussion  
This survey represents the most recent, comprehensive snapshot of anaesthetic activity and drug use 
in the United Kingdom. It provides unique detailed insight into drug/substance exposure during 
anaesthetic activity in the perioperative period.  In particular compared to the equivalent Activity 
survey performed in 2013.
1
 it provides considerably greater detail on use of analgesics, antibiotics, 
local anaesthetics, anti-emetics, intravenous colloids and blood products,  as well as providing more 
information on all drugs assessed in that survey, enabling an examination of trends in practice. This 
survey also provides information on reported exposure to other substances, such as latex, antiseptics 
(chlorhexidine and povidone-iodine), radiocontrast media, dyes and bone cement. 
 
Page 13 of 27 British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13 
 
As not all drug use was studied in NAP5 we can only comment on changes in choice of induction and 
maintenance agents, NMBAs and their reversal agents. We observed a substantial increase in the use 
of propofol for induction of anaesthesia for Caesarean section and a reduction in the use of 
thiopental. NAP5 identified such surgery as particularly high risk for Accidental Awareness during 
General Anaesthesia (AAGA) and thiopental was highlighted as a particular contributor to that.
9,10
 We 
also saw a reduction (by about a third) of use of nitrous oxide in all age groups. We are aware that 
nitrous oxide may have become less popular after the publication of the ENIGMA
11 
study
 
and some 
new hospital builds stopped including piped nitrous oxide to theatres. However the publication of 
ENIGMA-II has dispelled concerns about the safety of nitrous oxide, including in the elderly 
population.
12
 A recent Canadian publication noted that ENIGMA had reduced use of nitrous oxide 
amongst anaesthesiologists, but that ENIGMA-II had not led to any recovery in usage.
13
 Use of 
NMBAs has remained stable since the 2013 survey
1
, with almost half of patients undergoing general 
anaesthesia receiving NMBAs and with stable distribution across age groups. Regarding choice of 
NMBA, use of suxamethonium appears to have declined slightly, both overall (5.3% vs. 13% of cases 
in which an NMBA was used) and during Caesarean section (81% vs. 92%). Use of NMBA reversal 
agents has not increased overall but the proportion of uses of sugammadex has increased four-fold. 
With the drug soon to come off patent a further increase might be anticipated. Overall the static 
nature of NMBA use, the persistent under-use of reversal agents and the underwhelming use of 
neuromuscular monitoring reported in our accompanying paper
8
 indicates no evidence of 
improvement in practice since increased vigilance in this area was recommended in NAP5
9
 and 
described as mandatory in the AAGBI minimum standards for monitoring document in 2015.
14
  
 
This survey provides comprehensive and, to the best of our knowledge, previously unavailable data 
on the use of multiple drug classes including analgesics, antibiotics, local anaesthetics, anti-emetics, 
drugs affecting coagulation, intravenous colloids and blood products. These data will be useful 
primarily in acting as a denominator for the wider NAP6 project
1,2
 but we believe these data also 
have other uses. 
 
Our data show that analgesics are used in ≈90% of all procedures involving an anaesthetist and that 
opioids are used in virtually all general anaesthesia cases, a modest increase from NAP5 (92%). With 
increasing concerns about use of opioids for reasons of both immune function and dependence 
potential,
15
 this knowledge and the distribution of drugs used is useful of itself and for tracking 
changes. In total an estimated 3.6 million opioid drugs were administered in 3.1 million procedures, 
with fentanyl and morphine the dominant drugs, and oxycodone (about which some commentators 
have particular concerns)
16
 accounting for <2% of all opioid use and ranking as 5
th
 most frequently 
used opioid.  
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The widespread use of  local anaesthetics, which were administered in three quarters of all cases, 
and the distribution of drugs used indicates local and regional anaesthetic techniques were used in 
three quarters of cases, and with the previous results of NAP5, which indicated neuraxial anaesthesia 
being used for ≈30% of cases, suggests most suitable cases are receiving neuraxial, peripheral nerve 
block or local anaesthesia infiltration, the first two of which are associated with improved patient 
reported satisfaction.
17
 These data also provide numerator data – 2.3 million perioperative 
administration of local anaesthetics – which may be of value when measuring the safety impact of 
non-Luer connectors on avoidance of wrong route errors.
18,19
  
 
We have documented the use of anti-emetics in approximately three quarters of all cases with 
dexamethasone now administered routinely (60%) during general anaesthesia. With concerns about 
the impact of dexamethasone on cancer recurrence
20
 and the relatively modest impact of this drug 
on post-operative nausea and vomiting
21
 this is also a notable finding.  
 
Drugs affecting coagulation were used in ≈8% of all cases, with tranexamic acid used in ≈6% of all 
cases, in the majority of cardiac surgery cases and in one in five orthopaedics/trauma operations. 
This is likely a relatively new phenomenon, but with tranexamic acid now recommended to be 
offered to all patients undergoing surgery with anticipated blood loss >500 mls
22
 our findings act 
both as a benchmark, but also suggest that this recommendation may not be being widely applied.  
 
The use of IV colloids, is also of interest in relation both to blood product use (one administration in 
every 37 cases) and in the use of synthetic colloids (<2% of cases). Amongst the synthetic colloids the 
gelatins accounted for 90% of use, mostly during cardiac and vascular surgery. Starch-containing 
fluids are used in approximately 1 in 600 cases and while there was no particular pattern to their use 
(surgical specialty, patient age, ASA) it did include emergency cases and patients of ASA 3-4. The 26 
administrations of starch-containing fluids were reported from only 17 locations suggesting perhaps 
the use is clustered in certain hospitals. The use of starch containing fluid remains highly 
controversial and the European Medicines Agency recently recommended their suspension from 
sale.
23
 Based on our data this will have little impact on UK anaesthetic practice.  
 
Amidst the current threat of increasing antibiotic resistance,
24,25
  our data provide detailed 
information on antibiotic usage, which was reported for over half of the procedures and accounted 
for  almost 2 million administrations annually. Gentamicin, co-amoxiclav and cefuroxime being the 
most commonly used drugs – each used for approximately 500,000 uses. Orthopaedics/trauma and 
general surgery are the main specialties using antibiotics, but cardiac and neurosurgery, urology and 
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thoracic surgery are the specialties with the greatest proportion of cases receiving an antibiotic. The 
wide distribution of antibiotics used within specialties might perhaps hint at a lack of consistent 
application of best practice, but this would require further investigation.  
 
The choice of drugs administered was reported to be influenced by allergy history in almost 10% of 
cases and a history of antibiotic allergy influenced choice of teicoplanin or vancomycin in over a 
quarter of cases when either of these antibiotics were used. We did not collect information on the 
specific antibiotic(s) that patients reported allergy to, but it is likely that a history of penicillin allergy 
was dominant, as these drugs are common substitutes for penicillins and penicillin allergy is reported 
in up to 10% of the  general population and 20% of in patients.
26-28
 Importantly more than 90% of 
patients with a history of penicillin allergy are deemed not allergic when investigated via skin and 
drug provocation tests.
29
 The NAP6 baseline survey on anaesthetists’ perspectives and experiences of 
perioperative anaphylaxis reported that penicillins were the drugs anaesthetists were most 
concerned about and avoided most often. Notably teicoplanin, although prominent among 
suspected causative agents, was not frequently avoided.
30
 There is emerging evidence of teicoplanin 
as an important trigger of anaphylaxis events
31
 and it accounted for 28% of antibiotic-related 
anaphylaxis in one series.
8
 A growing body of evidence has shown that use of second-line (often 
more expensive) antibiotics has significant public health implications and increased healthcare costs 
with increased duration of treatment and hospital stay, and leads to higher rates of antibiotic 
resistance and infections including methicillin-resistant Staphylococcus aureus (MRSA), Clostridium 
difficile (C. diff) and vancomycin-resistant enterococcus (VRE).
32-34
 Our data provide additional 
evidence of use of second-line antibiotics, namely teicoplanin, driven by drug allergy history, adding 
further strength to calls from the international allergy community for robust programmes to tackle 
inaccurate labels of antibiotic allergy, improving antibiotic stewardship.
32-35
 
 
Chlorhexidine is a widely used antiseptic
36
 that has been increasingly reported as an emerging cause 
of allergy and perioperative anaphylaxis in particular,
37-42
 although its use still appears to be under-
recognised in the healthcare and especially in the perioperative setting and its potential to cause 
allergic reactions under-estimated by healthcare professionals.
43-45
 Despite its known ubiquitous use 
in the hospital, following infection prevention guidelines, our data evidenced reported chlorhexidine 
exposure in only ≈75% of all cases, mostly via skin prep by the anaesthetist and/or the surgeon. Very 
few cases of exposure were reported via urethral exposure and coated/impregnated central venous 
catheters (CVCs). National guidelines such as NICE CG74
46
, recommend use of chlorhexidine to 
prevent surgical site infections and many local hospital guidelines advocate the use of chlorhexidine 
prior to venous cannulation. We suspect our data likely reflects under-reporting due to under-
recognition of chlorhexidine exposure, for example due to lack of awareness of chlorhexidine being 
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present in many antiseptic alcohol wipes, urethral lubricants and CVCs. Conversely, it was 
unsurprising to find that povidone-iodine is used in ≈two fifths of cases and mostly via skin prep by 
the surgeon. 
 
Finally, our survey data suggest a latex-free environment was in place for only one fifth of cases.  
  
This survey adopted similar methodology to that used for the NAP5 activity survey.
4
 Discussion and 
details on the methodology used, in particular, the duration of the census over two days instead of a 
longer sampling time, the randomisation of specialist hospitals, and extrapolation of sample data to 
estimate the annual workload is already considered in the relevant paper.
8
 As also noted then, the 
large size of our sample data set means we can be confident that we have a true representation of 
the overall anaesthetic activity and allergen exposure in the UK and that it is reasonable to scale-up 
the 2-day sample data to estimate the annual data. However, where the sample size is small, 
variations in data captured or missed would have proportionately larger impacts on annual 
estimates, so these data should be treated more circumspectly. 
 
This survey suggests an annual caseload of 3 126 067, which is a 15% reduction compared to that 
reported in NAP5 (3 685 800). We are not aware of any comparable data against which to 
benchmark. Of note, the NAP6 annual estimate of Caesarean section caseload (171 579) is within 
<2% of that reported in NHS maternity data (174 720).
47
 We attempted to control for limitations in 
data collection by incorporating an estimated capture rate per hospital, accounting for 
uninterpretable forms, and calculating a scaling factor to include bank holidays. There are many 
factors that may have contributed to a fall in activity between 2013 and 2016, and these are 
discussed in the accompanying paper.
8
 However, the possibility also exists that we have missed a 
proportion of cases. If this is the case, we would have underestimated caseload, drug and allergen 
exposure, and activity by up to 15%. However, it would not impact on relative proportions and 
patterns of use/exposure within the dataset.    
 
Overall this extensive national survey of anaesthetic practice in the United Kingdom provides new 
insights into drug uses and allergen exposures in UK perioperative care. It is important for use as 
denominator in the main NAP6 analysis, and the data provide significant insights into many aspects 
of perioperative practice.  
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Figures 
 
 
Figure 1 – Use of all NMBA during general anaesthesia (whether individually or multiples), as 
a proportion of all general anaesthetic cases, N=12,213. 
 
 
Figure 2 - Use of NMBAs by age group and in Caesarean sections  
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Figure 3 – Use of analgesic agents in all cases 
This depicts use of each analgesic drug, whether in isolation or combined, n= 15,776. 
 
 
 
 
 
Figure 4 – Use of antibiotics in all procedures.  
This depicts use of each antibiotic, whether in isolation or combined, n= 15,790. 
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Figure 5 - Antibiotic use by specialty. Top panel indicates the proportion of all cases with 
antibiotics administered that fell in that surgical specialty. The lower panel indicates the 
proportion of cases in each surgical specialty receiving antibiotics.  
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Figure 6 – Distribution of individual antibiotics use by specialty 
 
 
 
Figure 7 - Use of local anaesthetics by intended conscious level 
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Appendix 1. Survey questionnaire 
 
 
Appendix 1 
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Appendix 2 
Calculation of Scaling Factor 
Number of weeks in the year 
It is not possible to multiply the weekly caseload by 52 due to Bank Holidays where activity will be 
reduced. Assuming activity on a Bank Holiday is similar to a weekend day the ‘effective’ number of 
weeks can be calculated. For 2016 the number of weeks used as a scaling factor to estimate annual 
activity was 50.74: 
There were 366 days in 2016 (leap year), and 52.28 weeks (366/7 = 52.29). 
Using the number of weekdays, a scaling a factor x, and y as the number of ‘effective’ weeks in 2016: 
5/7 * x = 52.29 and 253/366 * x = y 
Therefore x = 7*52.29/5 = y*366/253 
And y = (7*52.28*253) / (5 * 366) = 50.6 
Multiplication factor 
Number of returns in a week = number of returned forms *3.5 
Number of returns in a year (2016) = returned forms *3.5 * 50.6 
Estimated annual caseload = (returned forms * 3.5 * 50.6) / (proportion of interpretable forms * 
proportion of hospitals responding * individual site capture rate 
Multiplication factor = (3.5 * 50.6) / (0.98*0.96*0.96) = 196.09 
 
Page 28 of 27British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
